Your browser doesn't support javascript.
loading
CoRe study: COVID-19 and remdesivir: An insight into the current health planning and policy.
Samim, M M; Dhar, Debjyoti; Singh, Vikram; Nagaraja, B S; Shahyan, M S; Dey, Treshita; Parvin, Naznin; Dutta, Debayan; Shah, Rutul D; Bhavesh, M; Goyal, Sheeetal; Kariyappa, Mallesh; Saha, Subhrakamal; Goswami, Preetam; Das, Debarup; Shah, Shivani; Ramesh, K N; Shekhar, Jaipuriar.
Afiliación
  • Samim MM; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Dhar D; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Singh V; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Nagaraja BS; Department of Internal Medicine, Bowring and Lady Curzon Hospital, Bengaluru, Karnataka, India.
  • Shahyan MS; Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Dey T; Department of Radiation Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Parvin N; Department of Pediatrics, Lady Hardinge Medical College and Hospital, New Delhi, India.
  • Dutta D; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Shah RD; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Bhavesh M; Department of General Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Goyal S; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
  • Kariyappa M; Department of Pediatrics, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India.
  • Saha S; Department of General Medicine, Jawaharlal Nehru Hospital & Research Centre, Sector-9, Hospital Sector, Bhilai, Chhattisgarh, India.
  • Goswami P; Department of Pulmonary Medicine, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
  • Das D; Department of General Medicine, Medical College Hospital, Kolkata, West Bengal, India.
  • Shah S; Department of General Medicine, BJMC & Civil Hospital, Ahmedabad, Gujarat, India.
  • Ramesh KN; Department of General Medicine, Fortis Hospital, Cunningham Road, Bengaluru, Karnataka, India.
  • Shekhar J; Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
J Family Med Prim Care ; 11(8): 4671-4687, 2022 Aug.
Article en En | MEDLINE | ID: mdl-36352931
Introduction: The ongoing coronavirus disease-2019 (COVID-19) pandemic has witnessed rampant use of the repurposed drug, remdesivir, despite its conflicting evidence and rapidly changing guidelines. Methods: A cross-sectional, country-wide, questionnaire-based, electronic survey was conducted among the healthcare professionals involved in COVID-19 management from April 18 to May 18, 2021. Results: Out of 231 responses, 185 were included. Significantly, greater knowledge of trials was reported by the frontline healthcare professionals compared to those who are not involved in COVID-19 care. Medicine practitioners and pulmonologists expressed greater willingness to continue remdesivir (Odds ratio (OR) 5.329, 95% Confidence interval (CI) 2.31-12.291 and 5.063, 95% CI 1.414-18.129, respectively). The rationale attributed was personal experience, current guidelines, non-availability of any alternate antiviral drug, expert recommendations, and local hospital policy either alone (20%, 8.1%, 5.9%, 2.7%, and 2.2%, respectively) or in combination (46.5%, 39.5%, 29.2%, 21.1%, and 15.7%, respectively). Awareness of evidence and knowledge of landmark studies made no statistically significant impact on clinical decision-making. Improved clinical outcomes were reported by 10/22 (45.4%) practitioners who used remdesivir for unconventional indications. Conclusion: The study throws critical insights into the current perspectives of doctors on remdesivir in clinical management and its potential impact on current health planning strategies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: J Family Med Prim Care Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: J Family Med Prim Care Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: India